Psoriasis is a common, chronic skin disease that results mainly from the complex interplay
between T cells, dendritic cells, and inflammatory cytokines including TNF-α, IL-17, IL-12 …

Although anti-tumor necrosis factor (TNF) agents are highly effective in the treatment of
psoriasis, 2–5% of treated patients develop psoriasis-like skin lesions called paradoxical …

Chronic plaque psoriasis is a common debilitating skin disease. The identification of the
pathogenic role of the TNF/IL-23/TH17 pathway has enabled the development of targeted …

The definition of paradoxical psoriasis (PP) encompasses 2 main scenarios, namely,(i) new-
onset psoriasis in patients treated for a different disease and (ii) worsening as well as …

Anti-TNFs have revolutionized the management of numerous chronic inflammatory diseases
such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Although anti-TNF …

Psoriasis, a common chronic inflammatory skin disorder, impacts 2% to 3% of the population
globally. 1 Psoriasis is a prototypical type 3 (Th17) inflammatory disease, and the interleukin …

Abstract Today, anti‐12/IL23, anti‐IL17, and anti‐IL23 provide more efficacious and/or safer
treatment options for psoriasis. Though, anti‐TNF remains a gold standard in the therapy of …

Immunomodulation with anti‐TNF‐α is highly effective in the treatment of various immune‐
mediated inflammatory diseases, including hidradenitis suppurativa (HS). However, this may …

The growing availability of target therapies for psoriasis (biologicals) has dramatically
changed the prognosis of the disease. Currently, the therapeutic goal is represented by a …

There have been reports of paradoxical induction or worsening of psoriasis during treatment
with tumor necrosis factor (TNF) α agents (infliximab, etanercept, adalimumab, and …